Metformin hydrochloride tablets, as hypoglycemic drugs, have no clear weight loss effect on simple obesity, and there is a risk of exceeding the instructions for weight loss. Metformin hydrochloride is a first-line treatment drug for type 2 diabetes. It mainly regulates blood sugar by inhibiting liver glucose output and improving insulin resistance. The possible appetite loss and slight weight loss caused by metformin hydrochloride are the concomitant effects of diabetes treatment rather than the main mechanism.

Clinically, some patients with diabetes may have 2-3 kg weight loss after taking metformin hydrochloride, which is related to the reduction of food intake caused by gastrointestinal reaction caused by drugs. For non diabetes patients, the inhibitory effect of the drug on gluconeogenesis may affect normal energy metabolism, and there is no evidence of long-term safety. The drug instructions do not include weight loss as an indication. Common adverse reactions of metformin hydrochloride include gastrointestinal symptoms such as diarrhea and nausea, and long-term use may interfere with the absorption of vitamin B12. This drug is contraindicated for patients with severe liver and kidney dysfunction, as well as heart and lung failure. The 2016 International Association of Obesity Medicine guidelines clearly state that metformin is not recommended as a treatment for obesity.

It is recommended to manage weight through scientific diet control and regular exercise, maintain a daily calorie deficit of 200-300 calories, and engage in 150 minutes of moderate intensity exercise per week. For obese patients who meet medical standards, approved weight loss drugs such as Orlistat capsules and Liraglutide injection should be selected under the guidance of endocrinologists. Self consumption of hypoglycemic drugs for weight loss may lead to serious complications such as electrolyte imbalance and lactic acidosis.

Comments (0)
Leave a Comment
No comments yet
Be the first to share your thoughts!